Oxolife, a company associated with CataloniaBio  & HealthTech, has launched an international clinical trial to prove the effectiveness of its new treatment to improve the female fertility rate. It is the largest phase II study on female fertility conducted in Spain and it is aimed to improve the implantation of the embryo and increase the success rate of pregnancy, an unmet medical need as there is no therapy to improve embryonic implantation.

The trial has begun thanks to the round of  investment of 5 million euros that Oxolife captured in June 2020, which led Inveready together with the Center for ...

Mediktor, the healthtech company which provides a sophisticated pre-diagnosis medical assistant and a CataloniaBio & HealthTech  member, announced that it has raised a €11 million financing round to  keep on improving their elaborate technology and expand their international  presence.

The round was led by European healthtech growth capital investor MTIP. Existing investor Alta Life Sciences, also a CataloniaBio &  HealthTech member, participated as well.

Its technology identifies patient’s symptoms using natural language recognition, allowing the interpretation of more than one symptom at the same time. In the conversation with the medical assistant the questions require only simple responses and are ...

After postponing it due to COVID-19, the tenth edition of BIOSPAIN was held the last week of September, from 27 to 30, online all the days and in-person on 29 and 30 in Pamplona.  It has been one of the first major events in the sector during the pandemic with the participation of a thousand professionals, half of them in-person, from about 600 entities in 30 different countries.  More than 2,000 one-on-one meetings between national and international professionals and investors have been closed online and in person.

Sessions and round tables were the forum for discussion, to address issues ...

Nuage Therapeutics has announced the closing of a financing round by Sabadell Asabys, the investment vehicle managed by Asabys Partners, members of CataloniaBio & HealthTech. With this injection of capital, the spin-off will start its work discovering drugs aimed at therapeutic targets currently considered undruggable.

Based at the Barcelona Science Park, Nuage Therapeutics uses a proprietary assay to discover new drugs for the treatment of castration-resistant prostate cancer. Further pre-clinical programs will be announced in the coming months. The scientists behind Nuage Therapeutics have spent years investigating target proteins currently considered undruggable  due to their unique structural properties.

The financing ...

The health sector is a rising sector. Investment in health start-ups in Catalonia doubles in just two years, to over €200 million in 2020, and Barcelona has climbed to fifth place in Europe in rounds of investment in digital health. This is shown by the data collected in the BioRegion  of Catalonia Life Sciences and Healthcare Outlook 2020, by CataloniaBio & HealthTech and Biocat, which has motivated a series of special articles to give visibility to some of the projects that are representative of the strengths of the Catalan sector.

One of the keys to success is the previous innovative ...